4043-87-2Relevant articles and documents
-
Gilbertson
, p. 1737 (1972)
-
-
Yagi et al.
, p. 814 (1968)
-
An in situ FT-IR study on photocatalytic reaction at semiconductor-aqueous solution interface - Mechanism of photocatalytic N-cyclization of (S)-lysine
Ohtani, Bunsho,Yako, Takayuki,Samukawa, Yoriaki,Nishimoto, Sei-Ichi,Kanamura, Kiyoshi
, p. 91 - 92 (1997)
Photoinduced reaction occurring at an aqueous solution-semiconductor interface was analyzed in situ by reflection FT-IR spectroscopy. The photoinduced reflection spectral change, ΔR (= (R-R0)/R0), was recorded by using an IR cell consisting of a semiconductor (TiCO2 or CdS) thin film electrode, a thin layer of aqueous (S)-lysine solution, and a calcium fluoride window. Structure of adsorbed substrate and mechanism of photoinduced reaction were discussed.
-
Israeli,Cayouette
, p. 1523,1524-1527 (1971)
-
Recyclable Rh-PVP nanoparticles catalyzed hydrogenation of benzoic acid derivatives and quinolines under solvent-free conditions
Chaudhari, Chandan,Imatome, Hirotaka,Nishida, Yoshihide,Sato, Katsutoshi,Nagaoka, Katsutoshi
, p. 55 - 60 (2019/05/10)
Various transition metal nanoparticles, prepared by microwave-assisted alcohol reduction method were examined for hydrogenation of benzoic acid to cyclohexanecarboxylic acid under solvent-free conditions. Rh metal was the most effective catalyst over other metal catalyst. The catalyst showed moderate to high yield for the hydrogenation of substituted benzoic acid and substituted quinolines. Rh-PVP was recycled four times with a minor loss in catalytic activity.
Focal adhesion kinase inhibitor and use
-
Paragraph 0404; 0406; 0408, (2019/01/08)
The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.